Acepodia Announces First Patient Dosed in Phase 1 Trial of ACE723, a Novel Dual-Payload Antibody-Drug Conjugate ...Middle East

ACE723 is the first candidate from Acepodia's AD2C platform to enter human testing ALAMEDA, Calif., and TAIPEI, Nov. 5, 2026 /PRNewswire/ -- Acepodia (6976: TT), a clinical-stage biotechnology company developing next-generation cell therapies and antibody-drug conjugates, today announced...

Hence then, the article about acepodia announces first patient dosed in phase 1 trial of ace723 a novel dual payload antibody drug conjugate was published today ( Thursday 05/11/2026 - 10:17 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Acepodia Announces First Patient Dosed in Phase 1 Trial of ACE723, a Novel Dual-Payload Antibody-Drug Conjugate )

Also on site :

• Which Senate and governors races are still uncalled by The Associated Press
• Israel’s Herzog accepts vote results, opens talks on forming a government
• ‘Chicago Fire’ Star Joe Miñoso Reveals He Pitched Cruz’s Heartbreaking Exit Scene in 300th Episode (Exclusive)